The role of IκB kinase complex in the neurobiology of Huntington's disease

Neurobiology of Disease

Volumn 43, Issue 2, 2011, Pages 305-311

  Khoshnan, Ali ^a   Patterson, Paul H ^a  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

DNA damage; Htt cleavage; Huntington's disease; IKK ; Neuroinflammation

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ENZYME INHIBITOR; HUNTINGTIN; I KAPPA B KINASE BETA; I KAPPA B KINASE BETA INHIBITOR; MUTANT PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; DNA DAMAGE; DRUG ACTIVITY; ENZYME ACTIVATION; ENZYME REGULATION; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE PROGRESSION; HUMANS; HUNTINGTON DISEASE; I-KAPPA B KINASE; INFLAMMATION MEDIATORS;

EID: 79958191139     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.04.015     Document Type: Review

References (56)

1. Agou F., Ye F., Goffinont S., Courtois G., Yamaoka S., Israël A., et al. NEMO trimerizes through its coiled-coil C-terminal domain. J. Biol. Chem. 2002, 277:17464-17475.
2. Anest V., Hanson J.L., Cogswell P.C., Steinbrecher K.A., Strahl B.D., Baldwin A.S. A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature 2003, 423:659-663.
3. Anne S.L., Saudou F., Humbert S. Phosphorylation of huntingtin by cyclin-dependent kinase 5 is induced by DNA damage and regulates wild type and mutant huntingtin toxicity in neurons. J. Neurosci. 2007, 27:7318-7328.
4. Bae B.I., Xu H., Igarashi S., Fujimuro M., Agrawal N., Taya Y., et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 2005, 47:29-41.
5. Björkqvist M., Wild E.J., Thiele J., Silvestroni A., Andre R., Lahiri N., et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 2008, 205:1869-1877.
6. Boudreau R.L., Davidson B.L. RNAi therapeutics for CNS disorders. Brain Res. 2010, 1338:112-121.
7. Burguillos M.A., Deierborg T., Kavanagh E., Persson A., Hajji N., Garcia-Quintanilla A., et al. Caspase signaling controls microglia activation and neurotoxicity. Nature 2011, 9. Mar [Epub ahead of print].
8. Butterworth N.J., Williams L., Bullock J.Y., Love D.R., Faull R.L., Dragunow M. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum. Neuroscience 1998, 87:49-53.
9. Chariot A. The NF-kappaB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol. 2009, 19:404-413.
10. Cho I.H., Hong J., Suh E.C., Kim J.H., Lee H., Lee J.E., et al. Role of microglial IKK beta in kainic acid-induced hippocampal neuronal cell death. Brain 2008, 131:3019-3033.
11. Ghosh A., Roy A., Liu X., Kordower J.H., Mufson E.J., Hartley D.M., et al. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:18754-18759.
12. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
13. Godin J.D., Colombo K., Molina-Calavita M., Keryer G., Zala D., et al. Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron 2010, 67:392-406.
14. Graham R.K., Deng Y., Slow E.J., Haigh B., Bissada N., Lu G., et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006, 125:1179-1191.
15. Greer P.L., Greenberg M.E. From synapse to nucleus: calcium-dependent gene transcription in the control of synapse development and function. Neuron 2008, 59:846-860.
16. Gu X., Greiner E.R., Mishra R., Kodali R., Osmand A., Finkbeiner S., et al. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 2009, 64:828-840.
17. Hacker H., Karin M. Regulation and function of IKK and IKK-related kinases. Sci. STKE 2006, 357:re13.
18. Havel L.S., Wang C.E., Wade B., Huang B., Li S., Li X.J. Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation. Hum. Mol. Genet. 2011, 20:1424-1437.
19. Herrmann O., Baumann B., de Lorenzi R., Muhammad S., Zhang W., Kleesiek J., et al. IKK mediates ischemia-induced neuronal death. Nat. Med. 2005, 11:1322-1329.
20. Huang W.C., Ju T.K., Hung M.C., Chen C.C. Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. Mol. Cell 2007, 26:75-87.
21. Inta I., Paxian S., Maegele I., Zhang W., Pizzi M., Spano P., et al. Bim and Noxa are candidates to mediate the deleterious effect of the NF-kappa B subunit RelA in cerebral ischemia. J. Neurosci. 2006, 26:12896-12903.
22. Kaltschmidt B., Widera D., Kaltschmidt C. Signaling via NF-kappaB in the nervous system. Biochim. Biophys. Acta 2005, 1745:287-299.
23. Katyal S., McKinnon P.J. DNA strand breaks, neurodegeneration and aging in the brain. Mech. Ageing Dev. 2008, 129:483-491.
24. Khoshnan, A., Patterson, P.H., in preparation. IKKα regulates MeCP2 activity and the expression of BDNF.
25. Khoshnan A., Ko J., Patterson P.H. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1002-1007.
26. Khoshnan A., Ko J., Watkin E.E., Paige L.A., Reinhart P.H., Patterson P.H. Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J. Neurosci. 2004, 24:7999-8008.
27. Khoshnan A., Ko J., Tescu S., Brundin P., Patterson P.H. IKKα and IKKβ regulation of DNA damage-induced cleavage of huntingtin. PLoS One 2009, 4:e5768.
28. Kim D., Tsai L.H. Linking cell cycle reentry and DNA damage in neurodegeneration. Ann. N.Y. Acad. Sci. 2009, 1170:674-679.
29. Kim Y.J., Yi Y., Sapp E., Wang Y., Cuiffo B., Kegel K.B., et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12784-12789.
30. Kruman I.I., Wersto R.P., Cardozo-Pelaez F., Smilenov L., Chan S.L., Chrest F.J., et al. Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron 2004, 41:549-556.
31. Landles C., Sathasivam K., Weiss A., Woodman B., Moffitt H., Finkbeiner S., et al. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J. Biol. Chem. 2010, 285:8808-8823.
32. Lee D.F., Hung M.C. Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin. Cancer Res. 2008, 14:5656-5662.
33. Li Q., Lu Q., Bottero V., Estepa G., Morrison L., Mercurio F., Verma I.M. Enhanced NF-kappaB activation and cellular function in macrophages lacking IkappaB kinase 1 (IKK1). Proc. Natl. Acad. Sci. U. S. A. 2005, 102:12425-12430.
34. Lubin F.D., Sweatt J.D. The IkappaB kinase regulates chromatin structure during reconsolidation of conditioned fear memories. Neuron 2007, 55:942-957.
35. Madge L.A., May M.J. Inhibiting proinflammatory NF-kappaB signaling using cell penetrating NEMO binding domain peptides. Methods Mol. Biol. 2009, 512:209-232.
36. Maruyama H., Morino H., Ito H., Izumi Y., Kato H., Watanabe Y., et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010, 465:223-226.
37. Mattson M.P., Meffert M.K. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ. 2006, 13:852-860.
38. Ona V.O., Li M., Vonsattel J.P., Andrews L.J., Khan S.Q., Chung W.M., et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999, 399:263-267.
39. Raasch J., Zeller N., van Loo G., Merkler D., Mildner A., Erny D., Knobeloch K.P., et al. I{kappa}B kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-{kappa}B in the central nervous system. Brain 2011, 134:1184-1198.
40. Ratovitski T., Gucek M., Jiang H., Chighladze E., Waldron E., D'Ambola J., et al. Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J. Biol. Chem. 2009, 284:10855-10867.
41. Rodier F., Coppé J.P., Patil C.K., Hoeijmakers W.A., Muñoz D.P., Raza S.R., et al. Persistent DNA damage signaling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 2009, 11:973-979.
42. Saijo K., Winner B., Carson C.T., Collier J.G., Boyer L., Rosenfeld M.G., et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009, 137:47-59.
43. Silvestroni A., Faull R.L., Strand A.D., Möller T. Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Neuroreport 2009, 20:1098-10103.
44. Tai Y.F., Pavese N., Gerhard A., Tabrizi S.J., Barker R.A., Brooks D.J., et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007, 130:1759-1766.
45. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
46. Thompson L.M., Aiken C.T., Kaltenbach L.S., Agrawal N., Illes K., Khoshnan A., et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J. Cell Biol. 2009, 187:1083-1099.
47. Trejo A., Tarrats R.M., Alonso M.E., Boll M.C., Ochoa A., Velásquez L. Assessment of the nutrition status of patients with Huntington's disease. Nutrition 2004, 20:192-196.
48. Van Loo G., De Lorenzi R., Schmidt H., Huth M., Mildner A., Schmidt-Supprian M., et al. Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat. Immunol. 2006, 7:954-961.
49. Wexler N.S., Lorimer J., Porter J., Gomez F., Moskowitz C., Shackell E., et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3498-3503.
50. Wu Z.H., Miyamoto S. Induction of a pro-apoptotic ATM-NF-kappaB pathway and its repression by ATR in response to replication stress. EMBO J. 2008, 27:1963-1973.
51. Wu Z.H., Shi Y., Tibbetts R.S., Miyamoto S. Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science 2006, 311:1141-1146.
52. Zhang Y., Leavitt B.R., van Raamsdonk J.M., Dragatsis I., Goldowitz D., MacDonald M.E., et al. Huntingtin inhibits caspase-3 activation. EMBO J. 2006, 25:5896-5906.
53. Zhang X., Zhang G., Zhang H., Karin M., Bai H., Cai D. Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell 2008, 135:61-73.
54. Zhang F., Qian L., Flood P.M., Shi J.S., Hong J.S., Gao H.M. Inhibition of IkappaB kinase-beta protects dopamine neurons against lipopolysaccharide-induced neurotoxicity. J. Pharmacol. Exp. Ther. 2010, 333:822-833.
55. Zhu G., Wu C.J., Zhao Y., Ashwell J.D. Optineurin negatively regulates TNFalpha-induced NF-kappaB activation by competing with NEMO for ubiquitinated RIP. Curr. Biol. 2007, 17:1438-1443.
56. Zuccato C., Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 2010, 90:905-981.